Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, China.
Department of Obstetrics and Gynecology, General Hospital of Northern Theater Command, Shenyang, China.
ESC Heart Fail. 2024 Feb;11(1):91-98. doi: 10.1002/ehf2.14541. Epub 2023 Oct 11.
We aim to investigate the correlation between preoperative soluble suppression of tumourigenicity 2 (sST2) and postoperative myocardial remodelling and cardiac function in patients with valvular heart disease.
This retrospective study included patients who underwent heart valve surgery at the General Hospital of Northern Theatre Command from July 2019 to June 2020. Preoperative, early postoperative, and 1-month postoperative cardiac ultrasound data were collected. Multivariable linear regression was used to analyse the factors associated with preoperative sST2 and postoperative cardiac function parameters. A receiver operator characteristic curve analysis was used to analyse the predictive value of sST2 for left ventricular ejection fraction (LVEF) reduction at 1 month after surgery. This study included 156 patients. Left ventricular end-systolic volume (b = 0.125, P = 0.004), atrial fibrillation (b = 7.933, P = 0.003), and coronary artery disease (b = 5.826, P = 0.043) were correlated with the preoperative sST2 levels. Preoperative sST2 was independently associated with early postoperative left ventricular end-systolic volume (b = -0.136, P = 0.035), left ventricular end-diastolic volume (b = -0.225, P = 0.036), and LVEF (b = 0.056, P = 0.008). At 1 month after surgery, LVEF (r = -0.234, P = 0.023) and reduction in LVEF (r = -0.316, P = 0.002) were negatively correlated with preoperative sST2. The area under the receiver operator characteristic curve of preoperative sST2 in predicting LVEF reduction at 1 month was 0.646, with a sensitivity of 0.357 and a specificity of 0.918.
Preoperative sST2 levels are related to early postoperative myocardial remodelling and have a predictive value for the improvement of cardiac function 1 month after surgery.
本研究旨在探讨术前可溶性肿瘤抑制物 2（sST2）与瓣膜病患者术后心肌重构和心功能之间的相关性。
本回顾性研究纳入了 2019 年 7 月至 2020 年 6 月在北部战区总医院接受心脏瓣膜手术的患者。收集了患者术前、术后早期和术后 1 个月的心脏超声数据。采用多元线性回归分析与术前 sST2 及术后心功能参数相关的因素。采用受试者工作特征曲线分析 sST2 对术后 1 个月左心室射血分数（LVEF）降低的预测价值。本研究共纳入 156 例患者。左心室收缩末期容积（b=0.125，P=0.004）、心房颤动（b=7.933，P=0.003）和冠状动脉疾病（b=5.826，P=0.043）与术前 sST2 水平相关。术前 sST2 与术后早期左心室收缩末期容积（b=-0.136，P=0.035）、左心室舒张末期容积（b=-0.225，P=0.036）和 LVEF（b=0.056，P=0.008）独立相关。术后 1 个月，LVEF（r=-0.234，P=0.023）和 LVEF 降低（r=-0.316，P=0.002）与术前 sST2 呈负相关。术前 sST2 预测术后 1 个月 LVEF 降低的受试者工作特征曲线下面积为 0.646，灵敏度为 0.357，特异度为 0.918。
术前 sST2 水平与术后早期心肌重构有关，对术后 1 个月心功能的改善具有预测价值。
